Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibiotic studied in kids: first step toward better infection treatment

NCT ID NCT05217537

First seen Mar 19, 2026 · Last updated Jun 22, 2026 · Updated 9 times

Summary

This early-phase study tested a single dose of the antibiotic omadacycline (Nuzyra) in 23 children aged 8 to 17 who were hospitalized with bacterial infections. Researchers measured how the drug moved through the body and checked for side effects. The goal was to gather safety and dosing information, not to treat the infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Site 105

    Chicago, Illinois, 60611, United States

  • Site 106

    Cleveland, Ohio, 60611, United States

  • Site 107

    Orange, California, 92868, United States

  • Site 108

    Houston, Texas, 77030, United States

  • Site 109

    Little Rock, Arkansas, 72202, United States

  • Site 111

    Greenville, North Carolina, 27858, United States

  • Site 112

    Long Beach, California, 90806, United States

  • Site 113

    Philadelphia, Pennsylvania, 19104, United States

  • Site 114

    Aurora, Colorado, 80045, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

omadacycline (Nuzyra)

What this could lead to

If successful, this could help determine the right dose of omadacycline for children with bacterial infections.

What could go wrong

This is a very early, small study (23 children) that only looked at a single dose. It does not prove the drug works or is safe for long-term use.

Conditions

The condition(s) this trial relates to.

bacterial infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.